News Agency
Men's Weekly

Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

  • Written by PR Newswire
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases

SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) CEO Dr Steven...

Read more: Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and...

Defense Industry Jobs and Defence Recruitment: Building Careers That Shape National Security

The defence sector is one of the most important contributors to national security, innovation, and economic growth. Across Australia and worldwide, defense industry jobs offer opportunities for individuals to work in fields that combine technology, strategy, and service to the nation... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion